Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Zymeworks Inc. ZYME

Healthcare Biotechnology
Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:ZYME)

Fundamentals Snapshot (NDAQ:ZYME)

Current News (NDAQ:ZYME)

Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting

Business Wire March 14, 2023

Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results

Business Wire March 7, 2023

Zymeworks Announces Participation in Upcoming Investor Conferences

Business Wire February 28, 2023

Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call

Business Wire February 21, 2023

Zymeworks Announces Participation in Upcoming Investor Conferences

Business Wire January 25, 2023

Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

PR Newswire January 19, 2023

Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023

Business Wire January 4, 2023

Zymeworks Announces Participation in Upcoming Investor Conference

Business Wire December 21, 2022

Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab

PR Newswire December 21, 2022
View More News ››

Opinion & Analysis (NDAQ:ZYME)

Biopharma Receives FDA Fast Track Designation for Cancer Therapeutic

Streetwise Reports June 10, 2019
View More Opinion ››

Bullboard Posts (NDAQ:ZYME)

As some have noted..

Yesterday's quarterly and yearly results, smashed earnings and revenue estimates.  ZYME is ridiculously undervalued. ...
Gringotts - March 8, 2023

RE:ZYME contiuing it's trend up

And one she goes this morning. Over 8.70 and shows no signs of slowing down.
7Twiggy - November 15, 2022

ZYME contiuing it's trend up

Continues it's trend up.  Moved through 8.00 and showing a lot of strength these past two weeks.  Some good posts of Yahoo...
7Twiggy - November 10, 2022

I think we are headed into double digits sooner than later.

Another great day for Zymeworks.  Another 6 percent up.  Higher highs and lower lows the name of the game. I think we are...
7Twiggy - August 12, 2022

Looks to me like Zyme is on its way back.

Looks to me like Zyme is on its way back. Continue to add on positive moves up. Should see continued move up as we head to those...
7Twiggy - August 11, 2022

RE:News Release?

Sorry...I'm wrong. Galbraith is still in his position as CEO. Darn! Form 8-K (sec.gov)
Gringotts - August 6, 2022
View more Bullboard ››

Lithium Ionic Corp.

Lithium Ionic Corp.

Lithium Ionic Corp is a Canadian junior exploration company focused on developing commercial-grade lithium. It owns a 100 ...
View More »